Sleep

This is a focused baseline expansion, not new October clinical news or a complete sleep-topic monitoring run. Trial doses identify the evidence, not individualized dosing instructions.

• Low-dose doxepin (Silenor 3–6 mg): U.S.-approved for sleep maintenance, distinct from antidepressant doses. In the five-week primary trial, reported night-29 PSG wake time was 40.7 minutes with 6 mg and 60.5 with placebo; the raw mean difference is descriptive and no confidence interval is manufactured. Trial, Tables 1–3 · Label
• Ramelteon (Rozerem): U.S.-approved for sleep onset, acting on melatonin receptors. AASM 2017 weakly suggests it, whereas VA/DoD 2025 finds insufficient evidence for or against it. Label
• Suvorexant (Belsomra): An approved orexin antagonist for sleep onset/maintenance. Different DORAs are not assumed interchangeable. Label
• Trazodone: Off-label for insomnia; both guideline sources weakly suggest against chronic-insomnia use. A small crossover study found sleep effects alongside next-day performance impairment. Primary trial
• Mirtazapine: Off-label. DREAMING reported a week-6 adjusted ISI difference of −6.0 points (95% CI −9.0 to −3.0), with no significant benefit from week 12 onward. MIRAGE supplies additional short-term older-adult evidence and tolerability concerns. DREAMING · MIRAGE

VA/DoD 2025 guideline · AASM 2017 pharmacologic guideline

Baseline evidence; not new trial news. The explorer now distinguishes GABA-A modulation from orexin blockade. Zolpidem immediate release (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata/generics) represent Z-drugs; temazepam (Restoril) and triazolam (Halcion) represent benzodiazepines. Each entry identifies its formulation, approved insomnia use, trial follow-up, selected placebo-controlled adverse-event percentages and limitations. Ambien immediate release has a sleep-initiation indication; its evidence must not be transferred to Ambien CR. Zaleplon primarily addresses onset. Eszopiclone has controlled evidence through six months, which does not establish lasting remission after stopping.

Guidelines and approval remain separate. AASM 2017 gives weak recommendations for these agents in specified symptom patterns. VA/DoD 2025, recommendations 8–10 favors CBT-I as first-line and includes the three Z-drugs among conditional medication options, while suggesting against benzodiazepines for chronic insomnia. The two benzodiazepine labels specify short-term treatment, generally 7–10 days.

Safety context. The FDA Z-drug warning concerns complex sleep behaviors capable of serious injury or death. The benzodiazepine class warning covers abuse/addiction, dependence and potentially life-threatening withdrawal. Label adverse-event percentages are within-trial context and must not become a cross-drug ranking. No new efficacy plot or inferred confidence interval has been added for these five agents.

Sources: Ambien IR label, Lunesta label, six-month eszopiclone randomized trial, 2003, generic zaleplon label, Restoril label, Halcion label. Current labels checked 2026-10-03; individual label revision/posting dates are retained in the explorer.

Additional checked primary sources: Mayer et al., six-month ramelteon trial, March 2009 · Herring et al., two three-month suvorexant trials, 2016 · Trazodone U.S. prescribing information, revised March 2026 · Remeron U.S. prescribing information, revised November 2021

No additional finding was verified in the reviewed sources. Coverage remains partial; this is not a full-topic “no news” conclusion.

Coverage: Orzeyful availability checked and three Brilliance orexin-agonist registry records refreshed; selected insomnia, apnea and hypersomnolence news searches.

Remaining gaps: No complete insomnia, CBT-I/digital therapy, circadian or restless-legs study refresh. Orzeyful actual launch and DEA scheduling not verified; manufacturer still describes forthcoming availability. Full conference abstracts and safety-label changes not comprehensively reviewed.

Informal-source coverage: September 27 narcolepsy discussion repeats a November expectation pending scheduling, not verified launch: https://www.reddit.com/r/Narcolepsy/comments/1wr7at2/new_medication_made_in_japan/. No separate alert for repeated forecast.

Full coverage record.

Focused source verification for a two-condition explainer: adult insomnia and narcolepsy type 1. This does not constitute a complete sleep-topic review or advance the last successful all-topic check.

• Oveporexton regulatory precision: The August 5 FDA approval letter says that the statutory approval date and marketing depend on the DEA scheduling notice and amended labeling. The live U.S. product page still forecasts availability by November 2026, pending scheduling. Prefer “FDA approval announced; scheduling pending” to an unqualified availability claim. No actual launch was verified.
• Plot anchors: Selected month-3 daridorexant nighttime wakefulness and week-12 oveporexton daytime wakefulness results were checked directly against their labels. Endpoints, dose, sample, placebo difference and confidence interval are recorded in the explorer evidence file. These are separate within-trial examples, not a ranking. Daridorexant label; oveporexton label.
• Mechanism and alternatives: Rechecked current lemborexant and pitolisant labels. DORA clinical-mechanism wording remains “presumed”; pitolisant's exact clinical mechanism remains unclear. Retained the AASM recommendation for multicomponent CBT-I and distinction from sleep hygiene alone.
• Alixorexton limit: The August 24 sponsor announcement confirms phase 3 development and describes the phase 2 publication. Full journal text and original registry API fields were inaccessible in this check; no new registry status, approval or comparative safety claim is inferred.

Coverage is limited to the named primary labels, regulatory letter, guideline and sponsor sources. Existing OSA, circadian and restless-legs coverage is unchanged; no new broad surveillance claim is made.

September 9 publication — oveporexton / Orzeyful. Takeda announced NEJM publication of FirstLight and RadiantLight, the 12-week randomized narcolepsy type 1 trials already underlying the approval (168 and 105 participants). This adds peer-reviewed reporting for wakefulness, sleepiness, cataplexy and quality-of-life analyses. Frequent insomnia and urinary symptoms remain important; brief controlled follow-up does not establish long-term comparative benefit. The sponsor announcement and indexed journal abstract were checked, but full text and supplements were inaccessible for independent detailed appraisal. No additional numeric efficacy claims are inferred from the blocked paper. September 9 publication announcement; NEJM paper.

The official U.S. product page still gives expected availability by November 2026, pending DEA scheduling, checked September 14. No completed scheduling action or actual launch was established. This preserves the distinction between publication, approval and practical availability.

Current position. This category has two distinct advances: a potential oral treatment targeting airway neuromuscular control in OSA, and an orexin agonist with FDA approval announced for narcolepsy type 1, with statutory approval and marketing contingent on DEA scheduling. They address different disorders and cannot be treated as interchangeable ways to improve everyday sleep. The important research questions now include sustained function, treatment adherence, adverse effects and the populations that benefit.

AD109 / proposed Oxnimbi — Apnimed, OSA. The peer-reviewed SynAIRgy Phase 3 trial, NCT05813275, randomized 646 adults with mild-to-severe OSA who could not tolerate or refused positive airway pressure to aroxybutynin/atomoxetine or placebo for 26 weeks. The main analysis found an apnea–hypopnea index (AHI) difference of −4.0 events/hour (95% CI −6.4 to −1.6), with model-estimated reductions of 44.1% versus 17.6%. Oxygenation improved, but the PROMIS-Fatigue comparison was not significant. Adverse events caused treatment discontinuation in 21.2% versus 3.1%; dry mouth, nausea, insomnia and urinary hesitation were common. This is physiological efficacy with meaningful tolerability limitations, not a cardiovascular-outcomes trial. Published trial / PMID 42148495.

The sponsor's larger 55.6% AHI reduction headline uses an on-treatment analysis; it should not replace the main treatment-policy estimate above. FDA accepted the application on July 14, 2026; Apnimed's September 8 update reconfirms an FDA action target of February 28, 2027. It remains investigational in the U.S.; an accepted filing and proposed brand are not approval. Publication announcement explaining the estimand, current SEC-filed status.

Orzeyful / oveporexton / TAK-861 — Takeda, narcolepsy type 1. FDA announced approval of this oral selective orexin-2 receptor agonist on August 5, 2026. The approval letter makes the statutory approval date and marketing dependent on DEA scheduling; see the September 19 clarification above. The pivotal placebo-controlled, 12-week FirstLight and RadiantLight trials enrolled 168 and 105 participants respectively: NCT06470828, NCT06505031. Its approval concerns adult narcolepsy type 1, not general fatigue, insomnia, narcolepsy type 2 or idiopathic hypersomnia. FDA approval listing, trial design and conference findings.

FDA's label documents better objective wakefulness, subjective sleepiness and cataplexy. In FirstLight, placebo-adjusted Maintenance of Wakefulness Test improvements were 13.8 and 17.2 minutes for the two doses. Important limitations include frequent insomnia and urinary symptoms, creatine-phosphokinase elevations and increased LDL cholesterol. Longer follow-up is needed beyond the controlled 12-week period. Approval and availability are separate: Takeda expected launch after DEA scheduling, which its August 5 announcement anticipated within 90 days. A completed scheduling action or actual launch was not verified here. FDA label, approval and conditional launch statement.

Alixorexton / ALKS 2680 — Alkermes, broader hypersomnolence development. The 92-person Vibrance-1 Phase 2 trial, NCT06358950, had six blinded weeks and an optional seven-week open-label extension. Its publication was announced August 24, 2026: wakefulness and sleepiness improved; cataplexy reduction reached significance in the 6 mg group. Exploratory cognition/fatigue findings need confirmation. Brilliance Phase 3 studies are underway in narcolepsy types 1 and 2 (NCT07455383, NCT07502443, NCT07540897); Vibrance-3 studies idiopathic hypersomnia (NCT06843590). This remains investigational, and a positive extension cannot establish blinded long-term comparative benefit. Publication announcement, program identifiers and extension limitations.

Detection and broader sleep research. Track prospective validation of home tests and wearable alerts against suitable reference testing, including missed cases, false alerts, repeatability and whether detection improves patient outcomes. Keep detection, diagnosis and treatment selection separate. This initial pass did not establish a new diagnostic device or a population-screening benefit. Insomnia-specific development is expanded below; seltorexant's MDD-with-insomnia program remains cross-linked above rather than presented as a general-insomnia approval.

This selective expansion adds established treatment anchors and active human-development questions. Older studies and approvals below are baseline context, not new September 2026 news. The original apnea and narcolepsy evidence above is retained.

CBT-I and prescription digital therapy — SleepioRx. Multicomponent cognitive behavioral therapy for insomnia has a strong AASM recommendation; sleep hygiene alone is not an equivalent treatment. FDA cleared prescription Sleepio under K233577 on August 5, 2024, as an adjunct to usual care for chronic insomnia/insomnia disorder in adults. Its clearance summary includes the 336-person CrEDIT randomized trial, comparing digital CBT-I with online sleep-hygiene education, with a primary assessment at 10 weeks and follow-up through 24 weeks. This establishes an adult prescription-product baseline, not evidence for every consumer sleep app. Next: comparative delivery, remission, completion/adherence, durable daytime benefit and access; no firm new readout date verified. AASM guideline, FDA clearance and trial summary, current product description.

Insomnia medicines — daridorexant/Quviviq and the orexin-antagonist class. Daridorexant is U.S.-approved for adult insomnia involving sleep onset and/or maintenance and remains Schedule IV in the current label. Orexin antagonists reduce wake signaling; keep them separate from the orexin agonists being developed for pathological sleepiness. Pediatric use remains investigational. The March 30, 2026 sponsor topline for Phase 2 NCT05423717 included 165 treated children aged 10 to under 18, randomized to three doses or placebo for two weeks; the day-1 polysomnography total-sleep-time dose-response was significant (p=0.0185). This brief, sponsor-reported result cannot establish durable pediatric safety or benefit. Next: full results and the pediatric regulatory pathway. A July 30 sponsor update also forecast a U.S. daytime-functioning label-enabling study starting in the coming weeks; actual start/registration was not verified, and no firm next readout is established. Track new drugs and meaningful comparative results across the class, alongside dependence/rebound, next-day impairment and falls. Current U.S. label, pediatric topline, July development update.

Circadian-rhythm treatment — timing, light and melatonin. Track human studies of appropriately timed light/dark exposure, melatonin-based treatments and phase-guided delivery for defined circadian disorders. A 2024 randomized active-strategy trial, NCT03715465, studied 40 adults with delayed sleep-wake phase disorder for four weeks. Both groups received low-dose melatonin plus evening dim light and sleep scheduling; timing used measured versus estimated dim-light melatonin onset. Several measures improved over time, but measured-phase scheduling was not superior and total sleep time did not meet the multiplicity-adjusted significance threshold. This small study did not compare the entire package with placebo, and its findings do not independently establish bright-light-only efficacy. Next: larger comparisons, sustained phase alignment and daytime function; no dependable new result date verified. Original human study, trial registry.

Circadian drug development — tasimelteon/Hetlioz. Existing U.S. indications are adult Non-24-Hour Sleep-Wake Disorder and defined Smith-Magenis sleep-disturbance populations: capsules at age 16+ and suspension at ages 3–15. This is not a general insomnia or jet-lag approval. An FDA June 3, 2026 hearing notice concerns the proposed refusal of a jet-lag supplemental application; it scheduled a July 20 prehearing conference with the hearing date to follow. Next: verified docket/hearing outcome; the elapsed conference date does not establish completion, a decision or approval. No completed hearing or new firm date was verified in this bounded check. FDA label, internally revised January 2024, official hearing notice.

Restless legs — Nidra/NTX100 nerve stimulation. FDA granted De Novo DEN220059 on April 17, 2023 for a prescription device for medication-refractory moderate-to-severe primary restless legs syndrome. In the 133-person RESTFUL trial, NCT04874155, four blinded weeks produced CGI-I response rates of 45% versus 16% with sham and an IRLS difference of −3.4 points. Discomfort and skin irritation were generally mild; the trial reported no severe or serious device-related adverse events. The extension NCT05196828 was open-label and cannot establish long-term blinded comparative effectiveness. Next: durability, sleep/function, adherence, harms and access; no firm next event date verified. Also discover meaningful human drug and other device developments for RLS rather than limiting the scope to this anchor. FDA authorization, FDA indication review, RESTFUL publication, extension.

Orzeyful availability clarification — checked September 12, 2026. The official U.S. product page states expected availability by November 2026, pending DEA scheduling. This refines the earlier forecast above; it does not verify completed scheduling or launch. The page is a live sponsor statement, not a newly dated approval announcement.